Budget impact analysis of recombinant human prourokinase for injection in the treatment of acute myocardial infarction
YANG Yue1,2, ZHAO Rui1,2, CHEN Jia-yin1,2
1 School of Business Administration, Shenyang Pharmaceutical University, Liaoning Shenyang 110016, China; 2 International Food and Drug Policy and Law Research Center, Shenyang Pharmaceutical University, Liaoning Shenyang 110016, China
Abstract：Objective: At present, the incidence of myocardial infarction in China is increasing, giving patients and society a huge financial burden.The health care sector is actively exploring ways to improve the efficiency of medical security fund and to reduce the burden on patients.This study provided reference for the selection decision of health insurance catalog medicine, health insurance drug negotiation and determination of health insurance payment price. Methods: Based on the budget impact analysis model, the main data of treatment of acute myocardial infarction were analyzed by reviewing the literature, health statistics yearbook, CFDA Southern Medical Research Institute HDM system and 2014―2016 rhpro-UK sales data. The market composition of the main thrombolytic drugs for tre atment of acute myocardial infarction was compared and analyzed, and 2017―2021 within the next five years was predicted covering rhpro-UK not included in the health insurance catalog and rhpro-UK into the health insurance catalog two cases of health insurance fund tot al expenditure. Results: If rhpro-UK was included into the 2017 national health insurance catalog and did not cut prices, the next five years rhpro-UK health insurance spending accounted for the proportion of total expenditure of health insurance funds were 0.003 0%, 0.003 6%, 0.004 2%, 0.005 0% and 0.006 0% respectively, health insurance fund total expenditure will increase by about 12 195 200 yuan. If the price reduction rate was 5.9%, the total balance of health insurance would expend as 14 000 yuan within the next five years. Conclusion: With the increase of the price reduction rate of rhpro-UK, total expenditure of h ealth insurance fund will be further reduced.
2017, Vol. 15 
